

Clinical Trial Protocol

Iranian Registry of Clinical Trials

27 Jul 2026

Evaluation of the effects of topical application of micro emulsion prepared with black seed oil carrier of lipophilic active ingredients in the treatment of inflammatory disorders of Vulva vagina cavity

Protocol summary

Study aim

Evaluation of the effects of topical application of micro emulsion prepared with Black seed oil carrier of lipophilic active ingredients in the treatment of inflammatory disorders of vulva vaginal cavity.

Design

Clinical trial with control group and two intervention groups 1 and 2, three blind strains, non-randomized, phase 2-3, on 99 patients, uses the Covariate Adaptive Randomization (CAR) method to distribute confounding variables to the study groups..

Settings and conduct

The research will perform in the hospitals clinic of Alborz University of Medical Sciences. After taking a history, the Obstetricians specialist examines the patients and according to the conditions for entering the research selects the desired samples in case of a definite diagnosis of rhinosinusitis. After introducing and obtaining consent according to the CAR method, patients are placed in one of the three intervention groups and patients are evaluated in several stages. The letters A and B are used on the drugs, so the analyzer, patients and physician are not aware of the treatment method.

Participants/Inclusion and exclusion criteria

Inclusion criteria include all patients with vulvovaginitis over the age of 15 and under 60 years old, not using special drugs during the last week, normal Pap smear test as well as exclusion criteria include patients with allergy to natural products and placement during pregnancy and lactation period.

Intervention groups

Patients are intervened in three groups. In the control group, patients are treated with conventional oral tablets. In intervention group 1 Patients are treated with a topical solution containing micro emulsion made with flaxseed oil with conventional oral tablets. In intervention group 2 patients are treated with topical solution

containing micro emulsion of black seed oil.

Main outcome variables

Inflammation of the mucosa of the vulva vaginal cavity

General information

Reason for update

Acronym

IRCT registration information

IRCT registration number: **IRCT20210421051030N2**

Registration date: **2021-08-27, 1400/06/05**

Registration timing: **retrospective**

Last update: **2021-08-27, 1400/06/05**

Update count: **0**

Registration date

2021-08-27, 1400/06/05

Registrant information

Name

Behnam Mokri Savojbolaghi

Name of organization / entity

Country

Iran (Islamic Republic of)

Phone

+98 21 0000 0000

Email address

bms1909@iran.ir

Recruitment status

Recruitment complete

Funding source

Expected recruitment start date

2021-08-14, 1400/05/23

Expected recruitment end date

2021-08-20, 1400/05/29

Actual recruitment start date

empty

Actual recruitment end date

empty

Trial completion date

empty

Scientific title

Evaluation of the effects of topical application of micro emulsion prepared with black seed oil carrier of lipophilic active ingredients in the treatment of inflammatory disorders of Vulva vagina cavity

Public title

Evaluation of the effects of solution made with black seed oil in the treatment of vulvovaginitis

Purpose

Treatment

Inclusion/Exclusion criteria**Inclusion criteria:**

All vulvovaginitis patients over 15 years of age and under 60 years of age Not used immunosuppressive and antibiotics drugs during the last week Normal Pap smear test

Exclusion criteria:

Sensitivity to natural products Placement during pregnancy and lactation

Age

From **15 years** old to **60 years** old

Gender

Female

Phase

2-3

Groups that have been masked

- Participant
- Investigator
- Data and Safety Monitoring Board

Sample sizeTarget sample size: **99****Randomization (investigator's opinion)**

Not randomized

Randomization description**Blinding (investigator's opinion)**

Triple blinded

Blinding description

the researcher In order to blind the research for the patients and the treating physician, has prepared both samples of the drug and placebo in the same form so that they are not aware of the type of drug and placebo treatment. Sprays containing black seed oil micro emulsion and spray containing normal isotonic saline (placebo) in similar pumped bottles were marked with A and B marks, respectively. Also, oral antibiotic tablets and placebo tablets with A and B marks were placed in similar cans, respectively. The project clinical assistant then delivers the sprays and tablets, pre-marked A and B, based on the group that the patient has been categorized by sampling method. Also, the collected data with the same abbreviations A and B are delivered to the analyzer to be realized in the third strain of blinding.

Placebo

Used

Assignment

Parallel

Other design features**Secondary Ids**

empty

Ethics committees**1****Ethics committee****Name of ethics committee**

Ethics committee of Alborz University of Medical Sciences

Street address

Deputy of Research and Technology, Saffarian Alley, 45 meters of Golshahr

City

Karaj

Province

Alborz

Postal code

3198764653

Approval date

2021-06-19, 1400/03/29

Ethics committee reference number

IR.ABZUMS.REC.1400.107

Health conditions studied**1****Description of health condition studied**

Vulvovaginitis

ICD-10 code

N76

ICD-10 code description

Other inflammation of vagina and vulva

Primary outcomes**1****Description**

Inflammation of the mucosa of the vulva vaginal cavity

Timepoint

Before the intervention, During the intervention, after the intervention, one week after the intervention

Method of measurement

Visual Analogue Scale (Measure by Yes or No)

Secondary outcomes**1****Description**

Purulent vaginal discharge

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Questionnaire (Based on patient self-expression)

2

Description

Vaginal itching

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Questionnaire (Based on patient self-expression)

3

Description

Vaginal burning

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Questionnaire (Based on patient self-expression)

4

Description

Malodor

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Questionnaire (Based on patient self-expression)

5

Description

Painful intercourse

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Questionnaire (Based on patient self-expression)

6

Description

Urine itching (Dysuria)

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Questionnaire (Based on patient self-expression)

7

Description

Swelling of the mucosa

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Examination

8

Description

Redness of the mucosa

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Examination

9

Description

Mucosal lesions

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Examination

10

Description

Mucosal ulcers

Timepoint

Before the intervention, one week after the intervention

Method of measurement

Examination

Intervention groups

1

Description

Control group: the patients will treat by oral tablets (single dose of metronidazole 250 mg in bacterial vulvovaginitis and trichomoniasis and single dose of fluconazole 100 mg in candida vulvovaginitis). They also receive a solution containing normal saline isotonic as a placebo made by BMS scientific and research group.

Category

Treatment - Drugs

2

Description

Intervention group 1: the patients will treat by a topical solution containing micro emulsion prepared with black seed oil made by BMS scientific and research group plus oral tablets (single dose of metronidazole 250 mg in bacterial vulvovaginitis and trichomoniasis and single dose of fluconazole 100 mg in candida vulvovaginitis).

Category

Treatment - Drugs

3

Description

Intervention group 2: the patients will treat by a topical solution containing black seed oil micro emulsion and placebo oral tablets made by BMS scientific and research group.

Category

Treatment - Drugs

Recruitment centers

1

Recruitment center

Name of recruitment center

Kamali Hospital

Full name of responsible person

Bitá Badenosh

Street address

Shohada square ,Kamali st, Kamali educational and medical center

City

Karaj

Province

Alborz

Postal code

31348 77179

Phone

+98 26 3222 3021

Email

Kamali@abzums.ac.ir

Position

Clerk

Latest degree

Medical doctor

Other areas of specialty/work

Scholar

Street address

Iran university of medical sciences, Shahid hemmat highway

City

Tehran

Province

Tehran

Postal code

1449614535

Phone

+98 21 6670 7140

Fax**Email**

bms1909@iran.ir

Sponsors / Funding sources

1

Sponsor**Name of organization / entity**

Alborz University of Medical Science

Full name of responsible person

Hatam Godini

Street address

Deputy of Research and Technology, Saffarian Alley, 45 meters of Golshahr

City

Karaj

Province

Alborz

Postal code

3198764653

Phone

+98 26 3464 3705

Email

Reserch@abzums.ac.ir

Grant name**Grant code / Reference number****Is the source of funding the same sponsor organization/entity?**

No

Title of funding source

BMS science and research group

Proportion provided by this source

100

Public or private sector

Private

Domestic or foreign origin

Domestic

Category of foreign source of funding

empty

Country of origin**Type of organization providing the funding**

Persons

Person responsible for general inquiries

Contact**Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Behnam Mokri Savojbolaghi

Person responsible for scientific inquiries

Contact**Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Behnam Mokri Savojbolaghi

Position

Clerk

Latest degree

Medical doctor

Other areas of specialty/work

Scholar

Street address

Iran university of medical sciences, Shahid hemmat highway

City

Tehran

Province

Tehran

Postal code

1449614535

Phone

+98 21 6670 7140

Fax**Email**

bms1909@iran.ir

Person responsible for updating data

Contact**Name of organization / entity**

Iran University of Medical Sciences

Full name of responsible person

Behnam Mokri Savojbolaghi

Position

Clerk

Latest degree

Medical doctor

Other areas of specialty/work

Scholar

Street address

Iran university of medical sciences, Shahid hemmat
highway

City

Tehran

Province

Tehran

Postal code

1449614535

Phone

+98 21 6670 7140

Fax

Email

bms1909@iran.ir

Sharing plan

Deidentified Individual Participant Data Set (IPD)

Undecided - It is not yet known if there will be a plan to
make this available

Study Protocol

Undecided - It is not yet known if there will be a plan to
make this available

Statistical Analysis Plan

Undecided - It is not yet known if there will be a plan to
make this available

Informed Consent Form

Undecided - It is not yet known if there will be a plan to
make this available

Clinical Study Report

Undecided - It is not yet known if there will be a plan to
make this available

Analytic Code

Undecided - It is not yet known if there will be a plan to
make this available

Data Dictionary

Undecided - It is not yet known if there will be a plan to
make this available